Your prediction
Concert Pharmaceuticals Inc. Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Concert Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Concert Pharmaceuticals Inc. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Concert Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Concert Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -1.980% | -15.301% | -30.739% | -68.672% | -36.894% | -67.634% | -94.652% |
| Evolus Inc | 0.480% | -1.869% | 12.299% | -64.103% | -22.936% | -47.500% | -60.265% |
| Sangamo Therapeutics Inc. | -0.240% | -14.207% | -7.604% | -63.138% | -14.894% | -84.369% | -97.313% |
Comments
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for CNCE provided by MarketBeat
